Alnylam Pharmaceuticals (ALNY) ESG Score & Sustainability Data

$234.79 -0.77 (-0.33%)

(As of 12:04 PM ET)

Key ESG Takeaways for Alnylam Pharmaceuticals

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Alnylam Pharmaceuticals. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.

Alnylam Pharmaceuticals seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is false driven by its Gene therapy medication, Clinical research services, and Preclinical research services products.
On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in categories , , and . The negative contribution in the impact category is driven by its Gene therapy medication, Clinical research services, and Preclinical research services products.
To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Preclinical research services business, Alnylam Pharmaceuticals would improve its net impact ratio by 4 percentage points.

ALNY Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.

+63.9%

The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.: +70.3%
Most Wanted Workforce Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.: +58.1%
Society First Value set that emphasizes society impacts over other impacts.: +30.6%
Knowledge First Value set that emphasizes knowledge impacts over other impacts.: +86.3%
Health First Value set that emphasizes health impacts over other impacts.: +76.5%

Alnylam Pharmaceuticals ESG Score + Net Impact Profile

Negative	Score	Positive
-0.15	+3.44	+3.59
	+1.43	+1.43
	+1.91	+1.91
	+0.09	+0.09
-0.01	+0.03	+0.05
-0.14	-0.03	+0.11
-2.30	+2.09	+4.39
	+0.00	+0.00
	+4.39	+4.39
-0.00	+0.00	+0.00
-2.30	-2.30
-0.86	+4.58	+5.43
-0.80	+3.63	+4.43
-0.05	+0.67	+0.71
	0.00	+0.00
-0.00	0.00	+0.00
-0.00	+0.28	+0.28
-1.54	-1.52	+0.01
-0.62	-0.61	+0.01
-0.12	-0.11	+0.00
-0.08	-0.08	+0.00
-0.07	-0.07	+0.00
-0.65	-0.64	+0.00

Upright Model Version 0.4.0
ESG Data Last Updated: April 1, 2022

Ad Unstoppable Prosperity

FREE investing Class TOMORROW + 2 FREE Bonuses

Over the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stocks that outperform the market. It helps me understand which stocks are worth investing in now…AND which ones you should avoid at all costs! Tomorrow, during my LIVE intro to investing class online, my team will show you how exactly how it works

[YES, I'D LIKE TO REGISTER FOR CHARLES PAYNE'S UPCOMING INTRO TO INVESTING CLASS NOW!]

About Upright's Net Impact Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.

Alnylam Pharmaceuticals ESG Score - Frequently Asked Questions

How is Alnylam Pharmaceuticals doing in terms of sustainability?: According to The Upright Project, which measures holistic value creation and impact of companies, Alnylam Pharmaceuticals has a net impact ratio of 63.9%, indicating an overall positive sustainability impact. Alnylam Pharmaceuticals seems to create the most significant positive value in the categories of Physical diseases, Creating knowledge, and Taxes. On the other hand, these positive outcomes are achieved by using resources or causing negative impacts in the categories of Scarce human capital, Physical diseases, and Waste. Learn more on the sustainability of Alnylam Pharmaceuticals.

More ESG Stocks and Research Tools

Related Companies

Stock Lists

Sustainability Tools

This page (NASDAQ:ALNY) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) ESG Score & Sustainability Data

Key ESG Takeaways for Alnylam Pharmaceuticals

ALNY Impact Ratio

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Alnylam Pharmaceuticals ESG Score + Net Impact Profile

About Upright's Net Impact Model

Alnylam Pharmaceuticals ESG Score - Frequently Asked Questions

More ESG Stocks and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) ESG Score & Sustainability Data

Key ESG Takeaways for Alnylam Pharmaceuticals

ALNY Impact Ratio

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Alnylam Pharmaceuticals ESG Score + Net Impact Profile

Society

Knowledge

Health

Environment

About Upright's Net Impact Model

Alnylam Pharmaceuticals ESG Score - Frequently Asked Questions

More ESG Stocks and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools